Webinar – Use Basophils as Biomarker for Potency and Efficacy of Drugs in Development with Flow CAST®
Inhibitors of PI3K and BTK pathways are a large focus for pharmaceutical companies with several small molecule inhibitors currently at different stages of development. Enzymatic assays to measure the direct activity of compounds are available in the market with the limitation to not have information of the effect on the whole pathway controlled by these kinases.
With Flow CAST® we overcome this limitation, offering a robust assay to evaluate the functional effects on a cell target.
In this interesting webcast Michele Romano, PhD, Product Manager at BÜHLMANN Laboratories AG covers the following topics:
• Using basophils as surrogate markers for testing compounds in development
• Targeting the PI3K/BTK pathway in cancer
• Understanding the role and the opportunities of the immune cell signaling in basophils
• The Flow CAST® approach in testing the activity of kinases inhibitors
Michele Romano, PhD
Product Manager, Flow CAST® Assays
Collin Shaw
VP, Business Development
Social Links